Cyclin-dependent kinase inhibitors block proliferation of human gastric cancer cells

Surgery

Volumn 122, Issue 2, 1997, Pages 187-195

  Iseki, Hideaki ^a   Ko, Tien C ^a   Xue, Xiang Ying ^a   Seapan, Annie ^a   Hellmich, Mark R ^a   Townsend Jr , Courtney M ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; ISO OLOMOUCINE; OLOMOUCINE; PURINE DERIVATIVE; ROSCOVITINE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER CELL; CELL CYCLE S PHASE; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONFERENCE PAPER; DRUG EFFECT; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; STOMACH CANCER; SURVIVAL RATE;

EID: 0030868409     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-6060(97)90008-8     Document Type: Conference Paper

References (20)

1. Parkin DM, Läärä E, Muir CS. Estimates of the worldwide frequency of sixteen major cancers in 1980. Int J Cancer 1988;41:18497.
2. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1997. CA Cancer J Clin 1997;47:5-27.
3. van den Heuvel S, Harlow E. Distinct roles for cyclin-dependent kinases in cell cycle control. Science 1993;262:20504.
4. Morgan DO. Principles of CDK regulation. Nature 1995;374:1314.
5. Nurse P. Ordering S phase and M phase in the cell cycle. Cell 1994;79:547-50.
6. 1-to-S phase transition. Mol Cell Biol 1995;15:2612-24.
7. Sherr CJ, Roberts JM. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 1995;9:1149-63.
8. Vesely J, Havlicek L, Strand M, Blow JJ, Donella-Deana A, Pinna L, et al. Inhibition of cyclin-dependent kinases by purine analogues. Eur J Biochem 1994;224:771-86.
9. Meijer L. Chemical inhibitors of cyclin-dependent kinases. Trends Cell Biol 1996;6:393-7.
10. Parker CW, Entsch B, Letham DS. Photochemistry 1986;25:303-10.
11. Barranco SC, Townsend CM Jr, Casartelli C, Macik BG, Burger NL, Boerwinkle WR, et al. Establishment and characterization of an in vitro model system for human adenocarcinoma of the stomach. Cancer Res 1983;43:1703-9.
12. Barranco SC, Weintraub B, MacLean KK, Beasley EG, Jenkins VK, Townsend CM Jr. Relationship between glutathione levels and drug or radiation sensitivities in human gastric cancer cell lines in vitro. Invest New Drugs 1991;9:29-36.
13. Evers BM, Ko TC, Li J, Thompson EA. Cell cycle protein suppression and p21 induction in differentiating Caco-2 cells. Am J Physiol 1996;271:G722-7.
14. Dulic V, Lees E, Reed SI. Association of human cyclin E with a periodic G1-S phase protein kinase. Science 1992;257:1958-61.
15. Abraham RT, Acquarone M, Andersen A, Asensi A, Belle R, Berger F, et al. Cellular effects of olomoucine, an inhibitor of cyclin-dependent kinases. Biol Cell 1995;83:105-20.
16. Glab N, Labidi B, Qin LX, Trehin C, Bergounioux C, Meijer L. Olomoucine, an inhibitor of the cdc2/cdk2 kinases activity, blocks plant cells at the G1 to S and G2 to M cell cycle transitions. FEBS Lett 1994;353:207-11.
17. Akama Y, Yasui W, Yokozaki H, Kuniyasu H, Kitahara K, Ishikawa T, et al. Frequent amplification of the cyclin E gene in human gastric carcinomas. Jpn J Cancer Res 1995;86:617-21.
18. Tahara E. Genetic alterations in human gastrointestinal cancers: the application to molecular diagnosis. Cancer 1995;75:1410-7.
19. Tahara E. Molecular biology of gastric cancer. World J Surg 1995;19:484-90.
20. Akagi M, Yasui W, Akama Y, Yokozaki H, Tahara H, Haruma K, et al. Inhibition of cell growth by transforming growth factor beta 1 is associated with p53-independent induction of p21 in gastric carcinoma cells. Jpn J Cancer Res 1996;87:377-84.